Zanubrutinib for chronic lymphocytic leukemia in real-world China
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study is gathering real-world information on how well zanubrutinib (a targeted therapy) works for people with chronic lymphocytic leukemia (CLL). It includes both those starting treatment for the first time and those who have tried other treatments before, as long as they have taken zanubrutinib for at least 3 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with chronic lymphocytic leukemia (CLL) that needs treatment
- You have not had any treatment for CLL before, or your CLL came back or did not respond to earlier treatments
- You have taken or are currently taking zanubrutinib for at least 3 months
- You have had at least one check-up while on zanubrutinib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests a targeted therapy called zanubrutinib for people aged 80 and older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It may help control the disease with fewer side effects than standard chemotherapy.
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and bendamustine) as a first treatment for people with chronic lymphocytic leukemia (CLL) who have not had any previous therapy. The goal is to see if this combination is safe and effective.
This Phase 2 trial studies zanubrutinib taken after your DLBCL (a type of lymphoma) goes into remission, to help keep it controlled for longer. It focuses on people who have higher-risk features and can safely take this medicine.
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
Hear when a new CLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.